Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
2026. dec. 15.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Retraction Note: Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression.
2026. nov. 5.· Journal of experimental & clinical cancer research : CR· PUBMED
Publikáció
Modulation of Alzheimer's disease pathogenesis by the FGF-FGFR axis: therapeutic implications and translational perspectives.
2026. nov. 4.· Molecular biology reports· PUBMED
Publikáció
FGFR1-driven brachyury promotes endothelial-like differentiation of glioblastoma stem cells via SOX2/ZEB1/YAP1 signaling pathways.
2026. nov. 3.· Cellular signalling· PUBMED
Publikáció
A novel preclinical platform to study FGFR2 fusion-driven cholangiocarcinoma☆.
2026. nov. 3.· JHEP reports : innovation in hepatology· PUBMED
Publikáció
Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1.
2026. nov. 2.· Journal of hematology & oncology· PUBMED
Publikáció
Seven-year natural history of FGFR3::TACC3-GBM.
2026. nov. 2.· Journal of neuropathology and experimental neurology· PUBMED
Publikáció
First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.
2026. nov. 2.· Leukemia & lymphoma· PUBMED
Vizsgálat
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
2026. nov. 1.· PHASE2 · RECRUITING· CTGOV
Publikáció
Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.
2026. nov. 1.· Nature reviews. Clinical oncology· PUBMED
Publikáció
[Corrigendum] Combination of the FGFR4 inhibitor PD173074 and 5‑fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
2026. okt. 30.· Oncology reports· PUBMED
Publikáció
Structure-guided design and optimization of 3-amino-pyrazine-2-oxadiazole derivatives as novel FGFR2 inhibitors.
2026. okt. 30.· European journal of medicinal chemistry· PUBMED
Publikáció
FGFR Alterations in Bladder Cancer-From Molecular Pathogenesis to Precision Oncology.
2026. okt. 29.· JAMA oncology· PUBMED
Publikáció
A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.
2026. okt. 27.· Hepatology (Baltimore, Md.)· PUBMED
Publikáció
Evaluation of FGFR2, VEGFA, and MMP1 gene variants for ovarian cancer susceptibility among South Indian women: a hospital-based case-control study.
2026. okt. 25.· Molecular biology reports· PUBMED
Publikáció
Saving the Capillaries: FGFR1/KLB and MFG-E8 in Diabetic Hearts.
2026. okt. 22.· Circulation research· PUBMED
Publikáció
Combining DR5 activation with FGFR1 and VEGFR2 inhibition via an engineered TRAIL-based multimodal fusion protein for dual antitumor and antivascular activity in gastric and colorectal cancer models.
2026. okt. 21.· Journal of drug targeting· PUBMED
Publikáció
FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.
2026. okt. 20.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
Phase 2 study of fazpilodemab, a FGFR1/Klothoβ agonist, in metabolic dysfunction-associated steatohepatitis (MASH).
2026. okt. 17.· JHEP reports : innovation in hepatology· PUBMED
Publikáció
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
2026. okt. 15.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Integrated Analysis of the αKlotho-FGF23-FGFR Genetic Axis Reveals Determinants of Cardiovascular Risk in Chronic Kidney Disease.
2026. okt. 14.· American journal of nephrology· PUBMED
Publikáció
FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models.
2026. okt. 13.· BMC cancer· PUBMED
Publikáció
[Pathogenic mechanisms and targeted therapeutic advances of the FGF/FGFR signaling pathway in hematological malignancies].
2026. okt. 12.· Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences· PUBMED
Publikáció
pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.
2026. okt. 11.· International journal of molecular sciences· PUBMED
Publikáció
Acute monocytic leukemia with t(8;22)(p11;q11)/BCR::FGFR1, trisomy 8, and concurrent RUNX1/STAG2 mutations: A rare case report and literature review.
2026. okt. 10.· Leukemia research reports· PUBMED
Publikáció
HOOK3::FGFR1 Fusion in a Background of FGFR1 Amplification in Childhood B-Cell Acute Lymphoblastic Leukemia.
2026. okt. 10.· Pediatric blood & cancer· PUBMED
Publikáció
When the standard changes during the trial: Reflections on targeted therapy in FGFR2-rearranged cholangiocarcinoma.
2026. okt. 9.· Med (New York, N.Y.)· PUBMED
Publikáció
FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC.
2026. okt. 8.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED